IndieBio

Updated: Feb 7, 2020

IndieBio - Designing Drugs insilico: An Interview with Ed Painter of A2A Pharmaceuticals

Biomea Fusion, Inc., a precision oncology company dedicated to developing innovative medicines targeting genomically defined alterations...

A2A Pharmaceuticals Inc. Today Announced a Multi-target Co-development Agreement With Daewoong Pharmaceutical for AI-enhanced Oncology...